Drug Trial Radar · NCT01285765
Evaluate a Treatment Adapted to the PET Response Compared to a Standard Treatment, for Low Risk DLBCL CD 20+ Patients
Last checked: Nov 20, 2026Latest source record: Jul 14, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
650
Actual
Start
Dec 2010
Primary completion
May 23, 2020
Study completion May 23, 2020
Sponsor
- Lead sponsor
- The Lymphoma Academic Research OrganisationAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Central Hospital, Nancy, France
- First posted
- Jan 28, 2011
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
In this study, the investigators purpose is to evaluate the adaptation of treatment with early response based on PET scan results after 2 cycles of chemotherapy, for patient aged from 18 to 80 years, with low IPI DLBCL. This is an open randomized study. The primary endpoint is to evaluate the 3 years PFS with the aim to demonstrate the non inferiority of the experimental arm in comparison to standard arm: In standard arm, the patients will receive 6 cycles of R-CHOP 21 without taking into account of PET scan results after 2 cycles. In experimental arm, early good responder patients (defined as having a negative PET scan after 2 cycles, confirmed after 4 cycles) will receive only 4 cycles of R-CHOP 21. In both arms, if the PET scan remains positive after 4 cycles of chemotherapy, a biopsy exam is needed to confirm the failure and an intensive chemotherapy is then recommended. All of the patients, in both arms, will have an early evaluation with PET scan. All PET scan will be reviewed by a group of expert according to Deauville criteria defined by Meignan et al to adapt the decision after the 2nd cycle in experimental arm and after the 4th cycle for all patients. The final evaluation of response will be made according to 2007 Cheson's criteria.
Conditions
- DLBCL
Interventions
RCHOP21Drug
Prednisone-60 mg/m2: D1 D2 D3 D4 D5;Rituximab-375 mg/m2 : D1; Doxorubicin-50 mg/m2 D1;Cyclophosphamide-750 mg/m2:D1 Vincristine-1.4 mg/m2 :D1; G-CSF SC -5 microg/kg/day: D6 to D13
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression Free SurvivalTime frame: 3 years
Locations
83 sites in 2 countries. Site status is shown where the registry gives one.
ZNA Stuivenberg
Antwerp, Belgium
A. Z. Sint-Jan
Bruges, Belgium
Institut Jules Bordet
Brussels, Belgium
Université Libre de Bruxelles - Hôpital Erasme
Brussels, Belgium
Université Catholique de Louvain Saint Luc
Brussels, Belgium
Grand Hôpital de Charleroi
Charleroi, Belgium
UZ Gent
Ghent, Belgium
Hôpital Jolimont
Haine-Saint-Paul, Belgium
CHU de Liège
Liège, Belgium
Clinique Saint Joseph
Mons, Belgium
Clinique Saint Pierre
Ottignies, Belgium
Centre Hospitalier de Wallonie Picarde - CHwapi
Tournai, Belgium
CH de la Tourelle-Peltzer
Verviers, Belgium
UCL Mont Godinne
Yvoir, Belgium
CHU Angers
Angers, France
Centre Hospitalier Victor Dupouy
Argenteuil, France
CH d'ARRAS
Arras, France
CH d'Avignon
Avignon, France
CH de la Côte Basque
Bayonne, France
CHU de Besançon - Hôpital Jean Minjoz
Besançon, France
Institut Bergonié - Bordeaux
Bordeaux, France
Polyclinique Bordeaux Nord Aquitaine
Bordeaux, France
CH du Dr Duchenne
Boulogne-sur-Mer, France
CH de Bourg-en-Bresse
Bourg-en-Bresse, France
IHBN - CHU Côte de Nacre
Caen, France
CH de Cannes
Cannes, France
Médipôle de Savoie
Challes-les-Eaux, France
Hôpital de Chalon
Chalon-sur-Saône, France
CH de Chambéry
Chambéry, France
Hôpital d'Instruction des Armées Percy
Clamart, France
CHU Estaing - Clermont Ferrand
Clermont-Ferrand, France
Hôpital Pasteur
Colmar, France
CH de Compiègne
Compiègne, France
Centre Hospitalier Alpes Léman
Contamine-sur-Arve, France
CH Sud Francilien
Corbeil-Essonnes, France
Hôpital Henri MONDOR
Créteil, France
Chu Dijon
Dijon, France
CH de Dunkerque
Dunkirk, France
CHU de Grenoble - Hôpital Albert Michallon
Grenoble, France
CH Départemental Vendée
La Roche-sur-Yon, France
Showing 40 of 83 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.